There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Unity Biotechnology (UBX – Research Report) with bullish sentiments.
Allena Pharmaceuticals (ALNA)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.58.
According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Allena Pharmaceuticals is a Moderate Buy with an average price target of $7.50, an 876.6% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
Unity Biotechnology (UBX)
Wedbush analyst Andreas Argyrides reiterated a Buy rating on Unity Biotechnology today and set a price target of $4.00. The company’s shares closed last Tuesday at $1.86, close to its 52-week low of $1.43.
According to TipRanks.com, Argyrides is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $5.00 average price target, which is a 179.3% upside from current levels. In a report released yesterday, Roth Capital also upgraded the stock to Buy with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNA:
- Inspire Medical Systems’ Q4 & 2021 Preliminary Results Beat Estimates
- Needham Maintains a Buy Rating on Annexon Biosciences (ANNX)
- H.C. Wainwright Maintains Their Buy Rating on Annexon Biosciences (ANNX)
- H.C. Wainwright Thinks Ayala Pharmaceuticals’ Stock is Going to Recover
- Baudax Bio (BXRX) Gets a Buy Rating from Noble Financial
